Intuitive Surgical, Inc. (NASDAQ:ISRG) is Westwind Capital’s 4th Largest Position

Westwind Capital boosted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 67.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,334 shares of the medical equipment provider’s stock after acquiring an additional 21,963 shares during the quarter. Intuitive Surgical comprises about 6.5% of Westwind Capital’s investment portfolio, making the stock its 4th biggest position. Westwind Capital’s holdings in Intuitive Surgical were worth $26,693,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ISRG. Brevan Howard Capital Management LP grew its holdings in Intuitive Surgical by 215.6% during the 4th quarter. Brevan Howard Capital Management LP now owns 3,677 shares of the medical equipment provider’s stock valued at $1,240,000 after purchasing an additional 2,512 shares during the last quarter. Bayesian Capital Management LP bought a new position in shares of Intuitive Surgical during the fourth quarter valued at approximately $8,272,000. Groupama Asset Managment purchased a new stake in shares of Intuitive Surgical in the fourth quarter worth approximately $11,482,000. Public Sector Pension Investment Board lifted its stake in shares of Intuitive Surgical by 3.7% during the 4th quarter. Public Sector Pension Investment Board now owns 194,068 shares of the medical equipment provider’s stock worth $65,471,000 after acquiring an additional 6,934 shares during the last quarter. Finally, Profund Advisors LLC boosted its holdings in Intuitive Surgical by 18.7% during the 4th quarter. Profund Advisors LLC now owns 32,830 shares of the medical equipment provider’s stock valued at $11,076,000 after acquiring an additional 5,181 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $483.84 on Friday. The company’s 50-day simple moving average is $479.63 and its 200-day simple moving average is $434.04. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $496.48. The stock has a market capitalization of $171.93 billion, a P/E ratio of 83.13, a P/E/G ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. Intuitive Surgical’s revenue was up 14.5% compared to the same quarter last year. During the same period last year, the firm earned $1.18 earnings per share. On average, research analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Transactions at Intuitive Surgical

In related news, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the transaction, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the transaction, the director now owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 53,120 shares of company stock valued at $25,528,753 in the last quarter. 0.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Evercore ISI increased their target price on Intuitive Surgical from $410.00 to $475.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $380.00 to $510.00 in a report on Friday, August 2nd. Piper Sandler upped their target price on shares of Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. Truist Financial lifted their price target on shares of Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Finally, Robert W. Baird boosted their price target on Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus target price of $454.35.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.